BAT France: France’s Ban on Nicotine Pouches Could Undermine EU Harmonization and Public Health Goals

Aug.19.2025
BAT France: France’s Ban on Nicotine Pouches Could Undermine EU Harmonization and Public Health Goals
BAT France has welcomed the European Commission’s revision of the Tobacco Excise Directive (TED), which for the first time includes nicotine pouches under taxation, viewing it as an institutional recognition of low-risk alternatives. However, the company warns that excessively high taxation or unilateral bans by Member States (such as France’s plan to prohibit nicotine pouches) could harm public health objectives, undermine the EU single market, and encourage illicit trade.

Key Points:

 

  • Policy Dynamics: The EU plans to revise the Tobacco Excise Directive, including nicotine pouches under taxation for the first time, acknowledging their status as smoke-free alternatives.
  • Corporate Position: BAT France supports their inclusion in taxation but opposes excessive taxes and unilateral bans. The company advocates differentiated taxation to reflect harm reduction potential.
  • Core Controversy: France’s proposed ban on nicotine pouches is seen as a threat to EU regulatory coordination, single market integrity, and could stimulate the illicit market.
  • Evidence Basis: Nicotine pouches have contributed to declines in smoking rates in countries like Sweden. The current EU proposal, which taxes them the same as combustible tobacco, is criticized as disproportionate.

 


 

According to BAT France (August 18, official website), the company welcomed the European Commission’s July 16 proposal to revise the Tobacco Excise Directive (TED), which would bring nicotine pouches into the European tax system for the first time.

 

BAT France noted that the inclusion of nicotine pouches in taxation represents important institutional recognition of these smoke-free alternatives, which are increasingly used by adult smokers seeking to move away from combustible products.

 

At the same time, the company highlighted two risks: on the one hand, excessive taxes may reduce accessibility of these products; on the other hand, some Member States—including France—might attempt unilateral bans, which would disrupt Europe’s harmonization process.

 

Sébastien Charbonneau, Director of Public Affairs at BAT France, stated:


“It is important that nicotine pouches are recognized in European law. But it is crucial to adopt a differentiated tax policy that reflects their potential role in reducing harm for smokers.”

 


 

Building a European Harm Reduction Policy

 

In several countries, nicotine pouches have significantly contributed to reductions in smoking prevalence. In Sweden, their use has brought smoking rates down to the lowest in Europe (5.4%). Their inclusion in the Tobacco Excise Directive will facilitate regulation, monitoring, and taxation, but should not be used as a pretext to make them inaccessible through punitive taxation.

 


 

Matching Taxation with Risk Levels

 

The European Commission’s current proposal envisages very high excise duties on nicotine pouches, without clear distinction from combustible tobacco products. This approach violates the principle of proportionality and contradicts the EU’s stated public health objectives. Reduced-risk alternatives must be subject to differentiated taxation.

 


 

Acting Within the Existing European Framework

 

France has notified the European Commission of its plan to ban nicotine pouches. BAT France argues this move is premature and isolated, undermining the EU’s coordinated approach to regulating tobacco and reduced-risk alternatives.

 

Such unilateral action contradicts:

  • The harmonization goals of the Tobacco Excise Directive, which forms part of discussions on the EU’s next Multiannual Financial Framework (MFF);
  • The integrity of the single market, as it may create trade barriers and encourage the growth of France’s parallel market;
  • Regulatory consistency with the Tobacco Products Directive (TPD), which is currently under review and due to be discussed at the European level.

 

If nicotine pouches are made illegal in France but remain available in other EU markets, French consumption will not disappear—it will shift to the illicit market. France’s unilateral action would disrupt ongoing EU-level discussions and create legal uncertainty for economic stakeholders.

 


 

France Should Support Transparent Debate and EU Coordination

 

More than 50 parliamentarians have called for a democratic debate on the regulation of nicotine pouches. Three related bills have already been introduced in spring 2025. BAT France fully supports this call for democratic transparency and urges that France’s position be aligned with EU objectives: lowering smoking rates, ensuring regulatory consistency, and safeguarding the integrity of the internal market.

 

BAT France calls for:

  • Implementation of differentiated taxation that reflects product risk levels and supports public health goals;
  • Transparent parliamentary debate in France, respecting democratic processes and European commitments;
  • Avoidance of unilateral measures that could trigger legal, economic, and political tensions within the EU.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Korea’s MFDS sets 2026 plan to manage and disclose harmful constituents in tobacco products
Korea’s MFDS sets 2026 plan to manage and disclose harmful constituents in tobacco products
South Korea’s Ministry of Food and Drug Safety (MFDS) said it has established its 2026 work plan to systematically manage harmful constituents in tobacco products and disclose related information under the Tobacco Harmfulness Management Act, which took effect in November 2025.
Jan.16 by 2FIRSTS.ai
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
California and New Jersey advance bills to curb vape-waste risks tied to facility fires
California and New Jersey advance bills to curb vape-waste risks tied to facility fires
US state lawmakers and recycling groups are pursuing 2026 measures to address safety issues linked to vape waste through legislation, take-back programs and educational outreach. California’s State Assembly passed a bill to ban disposable vape pens, while New Jersey reintroduced an extended producer responsibility bill for e-cigarettes.
Feb.05 by 2FIRSTS.ai
Nebraska Lawmakers Consider Major Tax Hikes on Cigarettes, Vapes and Other Nicotine Products
Nebraska Lawmakers Consider Major Tax Hikes on Cigarettes, Vapes and Other Nicotine Products
Nebraska lawmakers are considering two tax bills targeting nicotine products. LB1124 would raise the cigarette tax from $0.64 to $1.64 per pack, while LB1238 would shift cigarettes to a 30% tax on the retailer’s purchase price and increase taxes on alternative nicotine and other tobacco products to 30%. The commentary argues the hikes could raise consumer costs, pressure small retailers, and increase cross-border shopping and illicit market activity.
Feb.04 by 2FIRSTS.ai
Malaysian Langkawi marine police seize vape devices and e-liquid worth US$43,902
Malaysian Langkawi marine police seize vape devices and e-liquid worth US$43,902
In Langkawi, Malaysia, the Marine Police seized various vape devices and e-liquid valued at RM178,400 (about US$43,902.99). Authorities believe the goods were intended to be smuggled out to a neighboring country.
Jan.15 by 2FIRSTS.ai
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11